Pancreatic Cyst
Conditions
Brief summary
This study aims to find out whether quantitative and qualitative analysis, including genetic mutation analysis, of samples obtained from patients with pancreatic cysts is associated with the risk of malignancy, and helpful in the differential diagnosis of mucinous and serous cysts. The study design is a single-arm prospective cohort observational study. Using blood, pancreatic cyst fluid, and pancreatic cyst tissue, genetic mutation analysis and measurement of various biomarkers are performed, and the relationship between these and malignancy or whether they are helpful in distinguishing mucinous and serous cysts is analyzed. The primary outcome is genetic variants of pancreatic cysts associated with malignancy. The secondary outcomes are factors including genetic variants that differentiate mucinous from serous cysts.
Detailed description
Pancreatic cysts, especially mucinous cysts, are precancerous lesions that can cause pancreatic cancer, and follow-up surveillance is important. However, there is a lack of clear medical evidence for the proper method and timing of follow-up, so the current follow-up strategies rely heavily on the opinions of experts. Although mucinous pancreatic cyst is known as a precancerous lesion, the incidence of cancer is about 1-5%. Therefore, if the risk of malignant disease can be more accurately predicted in patients with pancreatic cysts, patients with a high risk of malignant disease can be more intensively monitored and improved survival rates can be expected through early detection of pancreatic cancer. In addition, unnecessary medical resource consumption can be reduced by increasing the follow-up interval of pancreatic cyst patients with low risk of malignancy or not following them at all. To this end, in addition to imaging characteristics of pancreatic cysts, which are currently suggested as risk factors for malignancy in most guidelines for pancreatic cysts, differential diagnosis of pancreatic cysts based on new biomarkers such as genetic mutations and malignant risk assessment are necessary. Therefore, in this study, the investigators comprehensively analyze the blood, pancreatic cyst fluid, and pancreatic cyst tissue of patients with pancreatic cysts to explore biomarkers including genetic mutations that are helpful in the differential diagnosis of pancreatic cyst and the diagnosis of malignant tumors.
Interventions
OTHERNA (No intervention)
NA (No intervention)
Sponsors
Samsung Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Inclusion criteria
* Pancreatic cyst patients undergoing cyst aspiration or biopsy or surgical resection * Patients who gave written informed consent
Exclusion criteria
* Anyone who has not signed a written consent form. * Patients deemed unsuitable for research (severe infection, drug abuse, severe mental illness, etc.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Genetic variants of pancreatic cysts associated with malignancy assessed by next-generation sequencing | Through study completion, an average of 3 years | Genetic variants showing significant differences between pancreatic cysts with high-grade dysplasia or invasive cancer and the remaining pancreatic cysts, assessed through next-generation sequencing |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Genetic variants that differentiate mucinous from serous cysts assessed by next-generation sequencing | Through study completion, an average of 3 years | Genetic variants indicating significant differences between mucinous and serous cysts, as evaluated through next-generation sequencing |
Countries
South Korea
Contacts
Primary ContactYoung Hoon Choi, MD, PhD
Backup ContactJoo Kyung Park, MD, PhD
Outcome results
None listed